Lipocine Inc (LPCN)

Lipocine's stock has increased by 145% in the past six months, trading near its 52-week high. As of January 9, 2026, the share price was $8.01, a 63.80% increase from January 10, 2025. Key events include progress in the Phase 3 trial of LPCN 1154 for Postpartum Depression (PPD), reaching an 80% enrollment milestone in the PPD Phase 3 study, a promising interim safety profile in the Phase 3 trial of LPCN 1154 in PPD, financial results for the third quarter ended September 30, 2025, presentation of LPCN 2401 clinical data at ObesityWeek®, a progress update on the LPCN 1154 Phase 3 clinical trial in PPD, and H.C. Wainwright & Co. lowering its price target for Lipocine to $7.00 from $8.00, while maintaining a Buy rating.

Based on the available information, there is no specific indication of demand seasonality for Lipocine, Inc.'s products and services. The demand for its products is primarily driven by medical need, regulatory approvals, and market adoption rather than typical seasonal consumer patterns.

Lipocine, Inc. is a clinical-stage biopharmaceutical company focused on oral drug delivery technologies, particularly lipid-based formulations. Their goal is to improve the bioavailability of therapeutics, offering patient-friendly alternatives to injectable administrations. The company operates in the Healthcare sector, specifically in the Biotechnology and Pharmaceutical Products industry. Key products and pipeline candidates include TLANDO for male hypogonadism, LPCN 1144 for NASH, LPCN 1154 for postpartum depression, LPCN 1111 (TLANDO XR) for testosterone replacement therapy, LPCN 1148 for cirrhosis and sarcopenia, LPCN 1107 for preventing recurrent preterm birth, LPCN 2401 for obesity management, LPCN 2101 for women with epilepsy, and LPCN 2203 for essential tremor.

Lipocine, Inc. is headquartered in Salt Lake City, Utah, United States. The company aims to serve a global market and collaborates with pharmaceutical companies. Verity Pharma, one of its licensees, has filed a TLANDO drug submission in Canada.

Lipocine's brand reputation over the past year appears to be largely positive, driven by encouraging clinical trial progress and safety reviews for its pipeline products. The successful continuation of the Phase 3 trial for LPCN 1154 in postpartum depression, with no drug-related serious adverse events reported and positive safety reviews, significantly contributes to a favorable reputation. Enrollment milestones for this trial also reflect positively on the company's development capabilities. The FDA's recommendation to remove cardiovascular risk warnings from testosterone product labels could also be seen as a positive development for its TLANDO product. H.C. Wainwright & Co. lowering its price target for Lipocine from $8.00 to $7.00 could be perceived as a slight negative.

Lipocine Inc. has notable institutional and insider ownership. Approximately 9.11% to 10.16% of Lipocine's stock is owned by institutional investors, with 37 institutional owners and shareholders holding a total of 545,208 shares. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., Geode Capital Management, Llc, Susquehanna International Group, Llp, Renaissance Technologies Llc, FSMAX - Fidelity Extended Market Index Fund, State Street Corp, and Citadel Advisors Llc. Insider ownership has been reported as 37.09% (2.01 million shares) or 1.74% in December 2025. Some named insiders include Mr. John W. Higuchi and Mr. Jeffrey A Fink.